Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Predictive Biomarkers in Nephrology Around the Corner.

Perco P, Sharma K.

Kidney Int Rep. 2019 Nov 2;5(1):1-3. doi: 10.1016/j.ekir.2019.10.009. eCollection 2020 Jan. No abstract available.

2.

Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes.

Kammer M, Heinzel A, Willency JA, Duffin KL, Mayer G, Simons K, Gerl MJ, Klose C, Heinze G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, McCarthy MI, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; BEAt-DKD Consortium.

Kidney Int. 2019 Dec;96(6):1381-1388. doi: 10.1016/j.kint.2019.07.025. Epub 2019 Aug 30.

PMID:
31679767
3.

Computational Drug Screening Identifies Compounds Targeting Renal Age-associated Molecular Profiles.

Koppelstaetter C, Leierer J, Rudnicki M, Kerschbaum J, Kronbichler A, Melk A, Mayer G, Perco P.

Comput Struct Biotechnol J. 2019 Jun 25;17:843-853. doi: 10.1016/j.csbj.2019.06.019. eCollection 2019.

4.

Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease.

Perco P, Ju W, Kerschbaum J, Leierer J, Menon R, Zhu C, Kretzler M, Mayer G, Rudnicki M; Nephrotic Syndrome Study Network (NEPTUNE).

JCI Insight. 2019 Jun 20;4(12). pii: 128120. doi: 10.1172/jci.insight.128120. eCollection 2019 Jun 20.

5.

Patient-derived cell line models revealed therapeutic targets and molecular mechanisms underlying disease progression of high grade serous ovarian cancer.

Kreuzinger C, von der Decken I, Wolf A, Gamperl M, Koller J, Karacs J, Pfaffinger S, Bartl T, Reinthaller A, Grimm C, Singer CF, Braicu EI, Cunnea P, Gourley C, Smeets D, Boeckx B, Lambrechts D, Perco P, Horvat R, Berns EMJJ, Cacsire Castillo-Tong D.

Cancer Lett. 2019 Sep 10;459:1-12. doi: 10.1016/j.canlet.2019.05.032. Epub 2019 May 28.

PMID:
31150822
6.

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.

Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G.

Diabetologia. 2019 Jul;62(7):1154-1166. doi: 10.1007/s00125-019-4859-4. Epub 2019 Apr 17.

7.

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

Perco P, Pena M, Heerspink HJL, Mayer G; BEAt-DKD Consortium.

Kidney Int Rep. 2018 Dec 18;4(2):212-221. doi: 10.1016/j.ekir.2018.12.001. eCollection 2019 Feb. Review.

8.

Synthetic lethality guiding selection of drug combinations in ovarian cancer.

Heinzel A, Marhold M, Mayer P, Schwarz M, Tomasich E, Lukas A, Krainer M, Perco P.

PLoS One. 2019 Jan 25;14(1):e0210859. doi: 10.1371/journal.pone.0210859. eCollection 2019.

9.

Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast.

Marhold M, Tomasich E, Schwarz M, Udovica S, Heinzel A, Mayer P, Horak P, Perco P, Krainer M.

Oncotarget. 2018 Nov 20;9(91):36379-36391. doi: 10.18632/oncotarget.26372. eCollection 2018 Nov 20.

10.

Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes.

Heinzel A, Kammer M, Mayer G, Reindl-Schwaighofer R, Hu K, Perco P, Eder S, Rosivall L, Mark PB, Ju W, Kretzler M, Gilmour P, Wilson JM, Duffin KL, Abdalla M, McCarthy MI, Heinze G, Heerspink HL, Wiecek A, Gomez MF, Oberbauer R; BEAt-DKD Consortium.

Diabetes Care. 2018 Sep;41(9):1947-1954. doi: 10.2337/dc18-0532. Epub 2018 Jul 6.

11.

Validation of systems biology derived molecular markers of renal donor organ status associated with long term allograft function.

Perco P, Heinzel A, Leierer J, Schneeberger S, Bösmüller C, Oberhuber R, Wagner S, Engler F, Mayer G.

Sci Rep. 2018 May 3;8(1):6974. doi: 10.1038/s41598-018-25163-8.

12.

Endogenous factors and mechanisms of renoprotection and renal repair.

Perco P, Mayer G.

Eur J Clin Invest. 2018 May;48(5):e12914. doi: 10.1111/eci.12914. Epub 2018 Mar 7. Review.

PMID:
29460289
13.

Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information?

Perco P, Mayer G.

Kidney Int. 2018 Feb;93(2):308-310. doi: 10.1016/j.kint.2017.10.026.

PMID:
29389397
14.

Proteomic-Biostatistic Integrated Approach for Finding the Underlying Molecular Determinants of Hypertension in Human Plasma.

Gajjala PR, Jankowski V, Heinze G, Bilo G, Zanchetti A, Noels H, Liehn E, Perco P, Schulz A, Delles C, Kork F, Biessen E, Narkiewicz K, Kawecka-Jaszcz K, Floege J, Soranna D, Zidek W, Jankowski J.

Hypertension. 2017 Aug;70(2):412-419. doi: 10.1161/HYPERTENSIONAHA.116.08906. Epub 2017 Jun 26.

PMID:
28652472
15.

Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes.

Mayer G, Heerspink HJ, Aschauer C, Heinzel A, Heinze G, Kainz A, Sunzenauer J, Perco P, de Zeeuw D, Rossing P, Pena M, Oberbauer R; SYSKID Consortium.

Diabetes Care. 2017 Mar;40(3):391-397. doi: 10.2337/dc16-2202. Epub 2017 Jan 11.

PMID:
28077457
16.

Positioning of Tacrolimus for the Treatment of Diabetic Nephropathy Based on Computational Network Analysis.

Aschauer C, Perco P, Heinzel A, Sunzenauer J, Oberbauer R.

PLoS One. 2017 Jan 6;12(1):e0169518. doi: 10.1371/journal.pone.0169518. eCollection 2017.

17.

Validation of a protein panel for the noninvasive detection of recurrent non-muscle invasive bladder cancer.

Gogalic S, Sauer U, Doppler S, Heinzel A, Perco P, Lukas A, Simpson G, Pandha H, Horvath A, Preininger C.

Biomarkers. 2017 Nov;22(7):674-681. doi: 10.1080/1354750X.2016.1276628. Epub 2017 Jan 19.

PMID:
28010124
18.

Predictive Biomarkers for Linking Disease Pathology and Drug Effect.

Mayer B, Heinzel A, Lukas A, Perco P.

Curr Pharm Des. 2017;23(1):29-54. doi: 10.2174/1381612822666161006153639. Review.

PMID:
27719641
19.

Correction to "Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides".

Genovese F, Gualandi A, Taddia L, Marverti G, Pirondi S, Marraccini C, Perco P, Pelà M, Guerrini R, Amoroso MR, Esposito F, Martello A, Ponterini G, D'Arca D, Costi MP.

J Proteome Res. 2016 Oct 7;15(10):3944. Epub 2016 Sep 23. No abstract available.

PMID:
27662068
20.

Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.

Andorfer P, Heuwieser A, Heinzel A, Lukas A, Mayer B, Perco P.

BMC Syst Biol. 2016 Apr 18;10:33. doi: 10.1186/s12918-016-0278-z.

21.

Metallothioneins and renal ageing.

Leierer J, Rudnicki M, Braniff SJ, Perco P, Koppelstaetter C, Mühlberger I, Eder S, Kerschbaum J, Schwarzer C, Schroll A, Weiss G, Schneeberger S, Wagner S, Königsrainer A, Böhmig GA, Mayer G.

Nephrol Dial Transplant. 2016 Sep;31(9):1444-52. doi: 10.1093/ndt/gfv451. Epub 2016 Feb 3.

PMID:
26908771
22.

Renal microRNA- and RNA-profiles in progressive chronic kidney disease.

Rudnicki M, Perco P, D Haene B, Leierer J, Heinzel A, Mühlberger I, Schweibert N, Sunzenauer J, Regele H, Kronbichler A, Mestdagh P, Vandesompele J, Mayer B, Mayer G.

Eur J Clin Invest. 2016 Mar;46(3):213-26. doi: 10.1111/eci.12585. Epub 2016 Jan 21.

PMID:
26707063
23.

Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic.

De Paoli M, Perco P, Mühlberger I, Lukas A, Pandha H, Morgan R, Feng GJ, Marquette C.

Biomarkers. 2015;20(5):328-37. doi: 10.3109/1354750X.2015.1068867. Epub 2015 Jul 31.

PMID:
26329530
24.

Disease map-based biomarker selection and pre-validation for bladder cancer diagnostic.

De Paoli M, Perco P, Mühlberger I, Lukas A, Pandha H, Morgan R, Feng GJ, Marquette C.

Biomarkers. 2015 Jul 31:1-10. [Epub ahead of print]

PMID:
26227542
25.

Molecular disease presentation in diabetic nephropathy.

Heinzel A, Mühlberger I, Stelzer G, Lancet D, Oberbauer R, Martin M, Perco P.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv17-25. doi: 10.1093/ndt/gfv267. Review.

PMID:
26209734
26.

Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine.

Lambers Heerspink HJ, Oberbauer R, Perco P, Heinzel A, Heinze G, Mayer G, Mayer B.

Nephrol Dial Transplant. 2015 Aug;30 Suppl 4:iv105-112. doi: 10.1093/ndt/gfv210. Review.

PMID:
26209732
27.

A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetes.

Pena MJ, Heinzel A, Heinze G, Alkhalaf A, Bakker SJ, Nguyen TQ, Goldschmeding R, Bilo HJ, Perco P, Mayer B, de Zeeuw D, Lambers Heerspink HJ.

PLoS One. 2015 May 14;10(5):e0120995. doi: 10.1371/journal.pone.0120995. eCollection 2015.

28.

Protein interactome of muscle invasive bladder cancer.

Bhat A, Heinzel A, Mayer B, Perco P, Mühlberger I, Husi H, Merseburger AS, Zoidakis J, Vlahou A, Schanstra JP, Mischak H, Jankowski V.

PLoS One. 2015 Jan 8;10(1):e0116404. doi: 10.1371/journal.pone.0116404. eCollection 2015.

29.

A 3-biomarker-panel predicts renal outcome in patients with proteinuric renal diseases.

Neuwirt H, Perco P, Kainz A, Mühlberger I, Leierer J, Braniff SJ, Mayer B, Mayer G, Rudnicki M.

BMC Med Genomics. 2014 Dec 24;7:75. doi: 10.1186/s12920-014-0075-8.

30.

From molecular signatures to predictive biomarkers: modeling disease pathophysiology and drug mechanism of action.

Heinzel A, Perco P, Mayer G, Oberbauer R, Lukas A, Mayer B.

Front Cell Dev Biol. 2014 Aug 22;2:37. doi: 10.3389/fcell.2014.00037. eCollection 2014.

31.

The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB.

Anees M, Horak P, Schiefer AI, Vaňhara P, El-Gazzar A, Perco P, Kiesewetter B, Müllauer L, Streubel B, Raderer M, Krainer M.

Leuk Lymphoma. 2015 May;56(5):1440-9. doi: 10.3109/10428194.2014.953149. Epub 2014 Nov 5.

PMID:
25248880
32.

Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides.

Genovese F, Gualandi A, Taddia L, Marverti G, Pirondi S, Marraccini C, Perco P, Pelà M, Guerrini R, Amoroso MR, Esposito F, Martello A, Ponterini G, D'Arca D, Costi MP.

J Proteome Res. 2014 Nov 7;13(11):5250-61. doi: 10.1021/pr500510v. Epub 2014 Sep 29. Erratum in: J Proteome Res. 2016 Oct 7;15(10 ):3944.

PMID:
25196676
33.

Molecular pathogenesis of post-transplant acute kidney injury: assessment of whole-genome mRNA and miRNA profiles.

Wilflingseder J, Sunzenauer J, Toronyi E, Heinzel A, Kainz A, Mayer B, Perco P, Telkes G, Langer RM, Oberbauer R.

PLoS One. 2014 Aug 5;9(8):e104164. doi: 10.1371/journal.pone.0104164. eCollection 2014.

34.

Functional molecular units for guiding biomarker panel design.

Heinzel A, Mühlberger I, Fechete R, Mayer B, Perco P.

Methods Mol Biol. 2014;1159:109-33. doi: 10.1007/978-1-4939-0709-0_7. Review.

PMID:
24788264
35.

Proteome-based systems biology analysis of the diabetic mouse aorta reveals major changes in fatty acid biosynthesis as potential hallmark in diabetes mellitus-associated vascular disease.

Husi H, Van Agtmael T, Mullen W, Bahlmann FH, Schanstra JP, Vlahou A, Delles C, Perco P, Mischak H.

Circ Cardiovasc Genet. 2014 Apr;7(2):161-70. doi: 10.1161/CIRCGENETICS.113.000196. Epub 2014 Feb 26.

PMID:
24573165
36.

miRNA profiling discriminates types of rejection and injury in human renal allografts.

Wilflingseder J, Regele H, Perco P, Kainz A, Soleiman A, Mühlbacher F, Mayer B, Oberbauer R.

Transplantation. 2013 Mar 27;95(6):835-41. doi: 10.1097/TP.0b013e318280b385.

37.

Molecular models of the cardiorenal syndrome.

Heinzel A, Fechete R, Mühlberger I, Perco P, Mayer B, Lukas A.

Electrophoresis. 2013 Jun;34(11):1649-56. doi: 10.1002/elps.201200642. Epub 2013 May 8.

PMID:
23494759
38.

Evaluation of the Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles.

Siwy J, Zoja C, Klein J, Benigni A, Mullen W, Mayer B, Mischak H, Jankowski J, Stevens R, Vlahou A, Kossida S, Perco P, Bahlmann FH.

PLoS One. 2012;7(12):e51334. doi: 10.1371/journal.pone.0051334. Epub 2012 Dec 7.

39.

Increased renal versican expression is associated with progression of chronic kidney disease.

Rudnicki M, Perco P, Neuwirt H, Noppert SJ, Leierer J, Sunzenauer J, Eder S, Zoja C, Eller K, Rosenkranz AR, Müller GA, Mayer B, Mayer G.

PLoS One. 2012;7(9):e44891. Epub 2012 Sep 14.

40.

Molecular pathways and crosstalk characterizing the cardiorenal syndrome.

Mühlberger I, Mönks K, Fechete R, Mayer G, Oberbauer R, Mayer B, Perco P.

OMICS. 2012 Mar;16(3):105-12. doi: 10.1089/omi.2011.0121.

PMID:
22401656
41.

In-silico human genomics with GeneCards.

Stelzer G, Dalah I, Stein TI, Satanower Y, Rosen N, Nativ N, Oz-Levi D, Olender T, Belinky F, Bahir I, Krug H, Perco P, Mayer B, Kolker E, Safran M, Lancet D.

Hum Genomics. 2011 Oct;5(6):709-17.

42.

Linking molecular feature space and disease terms for the immunosuppressive drug rapamycin.

Bernthaler A, Mönks K, Mühlberger I, Mayer B, Perco P, Oberbauer R.

Mol Biosyst. 2011 Oct;7(10):2863-71. doi: 10.1039/c1mb05187c. Epub 2011 Jul 26.

PMID:
21789336
43.

Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy.

Fechete R, Heinzel A, Perco P, Mönks K, Söllner J, Stelzer G, Eder S, Lancet D, Oberbauer R, Mayer G, Mayer B.

Proteomics Clin Appl. 2011 Jun;5(5-6):354-66. doi: 10.1002/prca.201000136. Epub 2011 Apr 14.

PMID:
21491608
44.

Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.

Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK.

Cancer. 2011 Mar 15;117(6):1172-82. doi: 10.1002/cncr.25504. Epub 2010 Nov 8.

45.

Computational analysis workflows for Omics data interpretation.

Mühlberger I, Wilflingseder J, Bernthaler A, Fechete R, Lukas A, Perco P.

Methods Mol Biol. 2011;719:379-97. doi: 10.1007/978-1-61779-027-0_17.

PMID:
21370093
46.

Data and knowledge management in cross-Omics research projects.

Wiesinger M, Haiduk M, Behr M, de Abreu Madeira HL, Glöckler G, Perco P, Lukas A.

Methods Mol Biol. 2011;719:97-111. doi: 10.1007/978-1-61779-027-0_4.

PMID:
21370080
47.

Integrative bioinformatics analysis of proteins associated with the cardiorenal syndrome.

Mühlberger I, Moenks K, Bernthaler A, Jandrasits C, Mayer B, Mayer G, Oberbauer R, Perco P.

Int J Nephrol. 2010 Oct 21;2011:809378. doi: 10.4061/2011/809378.

48.

Integrative analysis of -omics data and histologic scoring in renal disease and transplantation: renal histogenomics.

Perco P, Oberbauer R.

Semin Nephrol. 2010 Sep;30(5):520-30. doi: 10.1016/j.semnephrol.2010.07.009. Review.

49.

Synthetic lethal hubs associated with vincristine resistant neuroblastoma.

Fechete R, Barth S, Olender T, Munteanu A, Bernthaler A, Inger A, Perco P, Lukas A, Lancet D, Cinatl J Jr, Michaelis M, Mayer B.

Mol Biosyst. 2011 Jan;7(1):200-14. doi: 10.1039/c0mb00082e. Epub 2010 Oct 28.

PMID:
21031175
50.

Adaptive trimmed t-statistics for identifying predominantly high expression in a microarray experiment.

Gleiss A, Sanchez-Cabo F, Perco P, Tong D, Heinze G.

Stat Med. 2011 Jan 15;30(1):52-61. doi: 10.1002/sim.4093. Epub 2010 Oct 20.

PMID:
20963766

Supplemental Content

Support Center